{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:02:45Z","timestamp":1792389765636,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5K12CA090625-20"],"award-info":[{"award-number":["5K12CA090625-20"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10549-021-06478-z","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:03:51Z","timestamp":1643155431000},"page":"491-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["An overview of genetic services delivery for hereditary breast cancer"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5233","authenticated-orcid":false,"given":"Sonya","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy B.","family":"Spalluto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuya","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"issue":"6","key":"6478_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"6478_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10689-017-0038-2","volume":"17","author":"GES Felix","year":"2018","unstructured":"Felix GES, Zheng Y, Olopade OI (2018) Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer 17(4):471\u2013483","journal-title":"Fam Cancer"},{"key":"6478_CR3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2741\/4185","volume":"18","author":"SE Filippini","year":"2013","unstructured":"Filippini SE, Vega A (2013) Breast cancer genes: beyond BRCA1 and BRCA2. Front Biosci (Landmark edition) 18:1358\u20131372","journal-title":"Front Biosci (Landmark edition)"},{"issue":"1","key":"6478_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.2007.53","volume":"40","author":"MR Stratton","year":"2008","unstructured":"Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40(1):17\u201322","journal-title":"Nat Genet"},{"issue":"7","key":"6478_CR5","doi-asserted-by":"crossref","first-page":"e208501","DOI":"10.1001\/jamanetworkopen.2020.8501","volume":"3","author":"S Gallagher","year":"2020","unstructured":"Gallagher S, Hughes E, Wagner S et al (2020) Association of a polygenic risk score with breast cancer among women carriers of high- and moderate-risk breast cancer genes. JAMA Netw Open 3(7):e208501\u2013e208501","journal-title":"JAMA Netw Open"},{"issue":"9","key":"6478_CR6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14737140.2019.1659730","volume":"19","author":"C Piccinin","year":"2019","unstructured":"Piccinin C, Panchal S, Watkins N, Kim RH (2019) An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Rev Anticancer Ther 19(9):787\u2013801","journal-title":"Expert Rev Anticancer Ther"},{"key":"6478_CR7","unstructured":"NCC Network (2021) Genetic\/familial high-risk assessment: breast, ovarian and pancreatic. (Version2.2021). Available from https:\/\/www-nccn-org.proxy.library.vanderbilt.edu\/. Accessed 14 Feb 2021"},{"issue":"3","key":"6478_CR8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3):676\u2013689","journal-title":"Am J Hum Genet"},{"issue":"3","key":"6478_CR9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/138920210791110951","volume":"11","author":"RE Ellsworth","year":"2010","unstructured":"Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL (2010) Breast cancer in the personal genomics era. Curr Genomics 11(3):146\u2013161","journal-title":"Curr Genomics"},{"issue":"6","key":"6478_CR10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41571-019-0179-3","volume":"16","author":"S Thavaneswaran","year":"2019","unstructured":"Thavaneswaran S, Rath E, Tucker K et al (2019) Therapeutic implications of germline genetic findings in cancer. Nat Rev Clin Oncol 16(6):386\u2013396","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"6478_CR11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329\u20131333","journal-title":"J Clin Oncol"},{"issue":"23","key":"6478_CR12","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"13","key":"6478_CR13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.30621","volume":"123","author":"D Cragun","year":"2017","unstructured":"Cragun D, Weidner A, Lewis C et al (2017) Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer 123(13):2497\u20132505","journal-title":"Cancer"},{"key":"6478_CR14","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","volume":"35","author":"CP Childers","year":"2017","unstructured":"Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35:3800\u20133806","journal-title":"J Clin Oncol"},{"issue":"1","key":"6478_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amepre.2010.09.027","volume":"40","author":"CA Bellcross","year":"2011","unstructured":"Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2011) Awareness and utilization of BRCA1\/2 testing among U.S. primary care physicians. Am J Prev Med 40(1):61\u201366","journal-title":"Am J Prev Med"},{"issue":"4","key":"6478_CR16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1055-9965.EPI-12-1280","volume":"22","author":"CA Bellcross","year":"2013","unstructured":"Bellcross CA, Leadbetter S, Alford SH, Peipins LA (2013) Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomarkers Prev 22(4):728\u2013735","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"23","key":"6478_CR17","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1002\/cncr.26166","volume":"117","author":"KF Trivers","year":"2011","unstructured":"Trivers KF, Baldwin LM, Miller JW et al (2011) Reported referral for genetic counseling or BRCA 1\/2 testing among United States physicians: a vignette-based study. Cancer 117(23):5334\u20135343","journal-title":"Cancer"},{"issue":"8","key":"6478_CR18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2013.51.4661","volume":"32","author":"ME Wood","year":"2014","unstructured":"Wood ME, Kadlubek P, Pham TH et al (2014) Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 32(8):824\u2013829","journal-title":"J Clin Oncol"},{"key":"6478_CR19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.amepre.2016.03.016","volume":"51","author":"T Jones","year":"2016","unstructured":"Jones T, Lockhart JS, Mendelsohn-Victor KE et al (2016) Use of cancer genetics services in African-American young breast cancer survivors. Am J Prev Med 51:427\u2013436","journal-title":"Am J Prev Med"},{"issue":"4","key":"6478_CR20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","volume":"13","author":"DE Levy","year":"2011","unstructured":"Levy DE, Byfield SD, Comstock CB et al (2011) Underutilization of BRCA1\/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med 13(4):349\u2013355","journal-title":"Genet Med"},{"issue":"14","key":"6478_CR21","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2014.58.5885","volume":"33","author":"R Jagsi","year":"2015","unstructured":"Jagsi R, Griffith KA, Kurian AW et al (2015) Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol 33(14):1584\u20131591","journal-title":"J Clin Oncol"},{"key":"6478_CR22","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2015.66.0019","volume":"34","author":"AM McCarthy","year":"2016","unstructured":"McCarthy AM, Bristol M, Domchek SM et al (2016) Health care segregation, physician recommendation, and racial disparities in BRCA1\/2 testing among women with breast cancer. J Clin Oncol 34:2610\u20132618","journal-title":"J Clin Oncol"},{"issue":"1","key":"6478_CR23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2015.04.029","volume":"138","author":"T Febbraro","year":"2015","unstructured":"Febbraro T, Robison K, Wilbur JS et al (2015) Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol 138(1):109\u2013114","journal-title":"Gynecol Oncol"},{"issue":"4","key":"6478_CR24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1055-9965.EPI-03-0545","volume":"14","author":"MD Schwartz","year":"2005","unstructured":"Schwartz MD, Lerman C, Brogan B et al (2005) Utilization of BRCA1\/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 14(4):1003\u20131007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"6478_CR25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2007.10.6377","volume":"26","author":"LR Susswein","year":"2008","unstructured":"Susswein LR, Skrzynia C, Lange LA, Booker JK, Graham ML 3rd, Evans JP (2008) Increased uptake of BRCA1\/2 genetic testing among African American women with a recent diagnosis of breast cancer. J Clin Oncol 26(1):32\u201336","journal-title":"J Clin Oncol"},{"issue":"2","key":"6478_CR26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10897-011-9462-x","volume":"21","author":"BD Riley","year":"2012","unstructured":"Riley BD, Culver JO, Skrzynia C et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151\u2013161","journal-title":"J Genet Couns"},{"issue":"31","key":"6478_CR27","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","volume":"33","author":"ME Robson","year":"2015","unstructured":"Robson ME, Bradbury AR, Arun B et al (2015) American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 33(31):3660\u20133667","journal-title":"J Clin Oncol"},{"key":"6478_CR28","unstructured":"American College of Surgeons. National Accreditation Program for Breast Centers. NAPBC Standards Manual 2018 Edition. 2018:77. https:\/\/accreditation.facs.org\/accreditationdocuments\/NAPBC\/Portal%20Resources\/2018NAPBCStandardsManual.pdf. Accessed 10 July 2021"},{"key":"6478_CR29","volume-title":"Next generation sequencing in cancer research, volume 2: from basepairs to bedsides","author":"H Fecteau","year":"2015","unstructured":"Fecteau H, Pal T (2015) Clinical considerations in the conduct of cancer next-generation sequencing testing and genetic counseling. In: Wu W, Choudhry H (eds) Next generation sequencing in cancer research, volume 2: from basepairs to bedsides. Springer International Publishing, Cham"},{"issue":"1","key":"6478_CR30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jgc4.1319","volume":"30","author":"E Boothe","year":"2021","unstructured":"Boothe E, Greenberg S, Delaney CL, Cohen SA (2021) Genetic counseling service delivery models: a study of genetic counselors\u2019 interests, needs, and barriers to implementation. J Genet Couns 30(1):283\u2013292","journal-title":"J Genet Couns"},{"key":"6478_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0628-5","author":"M Penon-Portmann","year":"2019","unstructured":"Penon-Portmann M, Chang J, Cheng M, Shieh JT (2019) Genetics workforce: distribution of genetics services and challenges to health care in California. Genet Med. https:\/\/doi.org\/10.1038\/s41436-019-0628-5","journal-title":"Genet Med"},{"issue":"3","key":"6478_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jpm9030033","volume":"9","author":"C Villegas","year":"2019","unstructured":"Villegas C, Haga SB (2019) Access to genetic counselors in the southern United States. J Pers Med 9(3):33","journal-title":"J Pers Med"},{"issue":"1","key":"6478_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10897-017-0158-8","volume":"27","author":"JM Hoskovec","year":"2018","unstructured":"Hoskovec JM, Bennett RL, Carey ME et al (2018) Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns 27(1):16\u201320","journal-title":"J Genet Couns"},{"key":"6478_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-0762-0","author":"S Reid","year":"2020","unstructured":"Reid S, Cragun D, Tezak A et al (2020) Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. Genet Med. https:\/\/doi.org\/10.1038\/s41436-020-0762-0","journal-title":"Genet Med"},{"issue":"20","key":"6478_CR35","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS et al (2017) Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol 35(20):2232\u20132239","journal-title":"J Clin Oncol"},{"issue":"1","key":"6478_CR36","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1200\/JOP.2016.013581","volume":"13","author":"P Whitworth","year":"2017","unstructured":"Whitworth P, Beitsch P, Arnell C et al (2017) Impact of payer constraints on access to genetic testing. J Oncol Pract 13(1):e47\u2013e56","journal-title":"J Oncol Pract"},{"issue":"1","key":"6478_CR37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12913-018-2957-5","volume":"18","author":"DD Stenehjem","year":"2018","unstructured":"Stenehjem DD, Au T, Sainski AM et al (2018) Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res 18(1):165","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"6478_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/14737159.2017.1267567","volume":"17","author":"D Cragun","year":"2017","unstructured":"Cragun D, Kinney AY, Pal T (2017) Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing. Expert Rev Mol Diagn 17(1):57\u201370","journal-title":"Expert Rev Mol Diagn"},{"issue":"4 Supplement","key":"6478_CR39","doi-asserted-by":"crossref","first-page":"PD1-08","DOI":"10.1158\/1538-7445.SABCS17-PD1-08","volume":"78","author":"E Hughes","year":"2018","unstructured":"Hughes E, Judkins T, Wagner S et al (2018) Abstract PD1-08: development and validation of a combined residual risk score to predict breast cancer risk in unaffected women negative for mutations on a multi-gene hereditary cancer panel. Cancer Res 78(4 Supplement):PD1-08-PD01-08","journal-title":"Cancer Res"},{"key":"6478_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab050","author":"Z Du","year":"2021","unstructured":"Du Z, Gao G, Adedokun B et al (2021) Evaluating polygenic risk scores for breast cancer in women of African ancestry. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djab050","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6478_CR41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41588-021-00797-z","volume":"53","author":"AR Martin","year":"2021","unstructured":"Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ (2021) Publisher correction: clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet 53(5):763","journal-title":"Nat Genet"},{"issue":"12","key":"6478_CR42","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","volume":"320","author":"J Mersch","year":"2018","unstructured":"Mersch J, Brown N, Pirzadeh-Miller S et al (2018) Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA 320(12):1266\u20131274","journal-title":"JAMA"},{"issue":"1","key":"6478_CR43","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1186\/s12885-015-1934-1","volume":"15","author":"BK Eccles","year":"2015","unstructured":"Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM (2015) Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer 15(1):936","journal-title":"BMC Cancer"},{"issue":"9","key":"6478_CR44","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.6004\/jnccn.2014.0128","volume":"12","author":"MJ Hall","year":"2014","unstructured":"Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN (2014) Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 12(9):1339\u20131346","journal-title":"J Natl Compr Canc Netw"},{"issue":"34","key":"6478_CR45","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","volume":"34","author":"J Balma\u00f1a","year":"2016","unstructured":"Balma\u00f1a J, Digiovanni L, Gaddam P et al (2016) Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. J Clin Oncol 34(34):4071\u20134078","journal-title":"J Clin Oncol"},{"issue":"5","key":"6478_CR46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424","journal-title":"Genet Med"},{"issue":"10","key":"6478_CR47","doi-asserted-by":"crossref","first-page":"e1913900","DOI":"10.1001\/jamanetworkopen.2019.13900","volume":"2","author":"R Karam","year":"2019","unstructured":"Karam R, Conner B, LaDuca H et al (2019) Assessment of diagnostic outcomes of RNA genetic testing for hereditary cancer. JAMA Netw Open 2(10):e1913900\u2013e1913900","journal-title":"JAMA Netw Open"},{"key":"6478_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","volume":"1","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Hughes E, Handorf EA et al (2017) Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. JCO Precis Oncol 1:1\u201312","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"6478_CR49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/gim.2017.96","volume":"20","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Gupta T, Hall E et al (2018) Racial\/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Med 20(2):234\u2013239","journal-title":"Genet Med"},{"key":"6478_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02785","author":"AW Kurian","year":"2021","unstructured":"Kurian AW, Ward KC, Abrahamse P et al (2021) Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012\u20132019. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.20.02785","journal-title":"J Clin Oncol"},{"issue":"4","key":"6478_CR51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10689-019-00144-6","volume":"18","author":"MK Ndugga-Kabuye","year":"2019","unstructured":"Ndugga-Kabuye MK, Issaka RB (2019) Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European. Fam Cancer 18(4):465\u2013469","journal-title":"Fam Cancer"},{"issue":"2","key":"6478_CR52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/gte.2005.9.167","volume":"9","author":"M Watson","year":"2005","unstructured":"Watson M, Kash KM, Homewood J, Ebbs S, Murday V, Eeles R (2005) Does genetic counseling have any impact on management of breast cancer risk? Genet Test 9(2):167\u2013174","journal-title":"Genet Test"},{"issue":"10","key":"6478_CR53","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncponc0930","volume":"4","author":"DH Roukos","year":"2007","unstructured":"Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol 4(10):578\u2013590","journal-title":"Nat Clin Pract Oncol"},{"issue":"8","key":"6478_CR54","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.2005.10.035","volume":"23","author":"SA Narod","year":"2005","unstructured":"Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23(8):1656\u20131663","journal-title":"J Clin Oncol"},{"issue":"7","key":"6478_CR55","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/s41436-018-0361-5","volume":"21","author":"K Lee","year":"2019","unstructured":"Lee K, Seifert BA, Shimelis H et al (2019) Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genet Med 21(7):1497\u20131506","journal-title":"Genet Med"},{"issue":"9","key":"6478_CR56","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","volume":"13","author":"N Tung","year":"2016","unstructured":"Tung N, Domchek SM, Stadler Z et al (2016) Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13(9):581\u2013588","journal-title":"Nat Rev Clin Oncol"},{"issue":"28","key":"6478_CR57","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","volume":"29","author":"C Cybulski","year":"2011","unstructured":"Cybulski C, Woko\u0142orczyk D, Jakubowska A et al (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29(28):3747\u20133752","journal-title":"J Clin Oncol"},{"issue":"9","key":"6478_CR58","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA Oncol 304(9):967\u2013975","journal-title":"JAMA Oncol"},{"issue":"33","key":"6478_CR59","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203\u20135209","journal-title":"J Clin Oncol"},{"issue":"2","key":"6478_CR60","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","volume":"182","author":"D Cragun","year":"2020","unstructured":"Cragun D, Weidner A, Tezak A, Clouse K, Pal T (2020) Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers. Breast Cancer Res Treat 182(2):421\u2013428","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6478_CR61","doi-asserted-by":"crossref","first-page":"e196400","DOI":"10.1001\/jamaoncol.2019.6400","volume":"6","author":"AW Kurian","year":"2020","unstructured":"Kurian AW, Ward KC, Abrahamse P et al (2020) Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer. JAMA Oncol 6(4):e196400","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"6478_CR62","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.2020.38.15_suppl.1508","volume":"38","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, Brower J, Symecko H et al (2020) Uptake of oophorectomy in women with findings on multigene panel testing: results from the Prospective Registry of Multiplex Testing (PROMPT). J Clin Oncol 38(15_suppl):1508","journal-title":"J Clin Oncol"},{"issue":"6","key":"6478_CR63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533","journal-title":"N Engl J Med"},{"issue":"25","key":"6478_CR64","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"8","key":"6478_CR65","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753\u2013763","journal-title":"N Engl J Med"},{"issue":"9","key":"6478_CR66","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967\u2013975","journal-title":"JAMA"},{"issue":"15","key":"6478_CR67","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, Moller P et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547\u20131553","journal-title":"J Clin Oncol"},{"key":"6478_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1196","author":"CC Conley","year":"2020","unstructured":"Conley CC, Ketcher D, Reblin M et al (2020) The big reveal: family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer. J Genet Couns. https:\/\/doi.org\/10.1002\/jgc4.1196","journal-title":"J Genet Couns"},{"issue":"3","key":"6478_CR69","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jgc4.1356","volume":"30","author":"D Cragun","year":"2021","unstructured":"Cragun D, Weidner A, Tezak A, Clouse K, Pal T (2021) Family communication of genetic test results among women with inherited breast cancer genes. J Genet Couns 30(3):701\u2013709","journal-title":"J Genet Couns"},{"issue":"11","key":"6478_CR70","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/gim.2018.26","volume":"20","author":"S Lieberman","year":"2018","unstructured":"Lieberman S, Lahad A, Tomer A et al (2018) Familial communication and cascade testing among relatives of BRCA population screening participants. Genet Med 20(11):1446\u20131454","journal-title":"Genet Med"},{"key":"6478_CR71","first-page":"260847","volume":"2013","author":"D Cragun","year":"2013","unstructured":"Cragun D, Pal T (2013) Identification, evaluation, and treatment of patients with hereditary cancer risk within the United States. ISRN Oncol 2013:260847","journal-title":"ISRN Oncol"},{"key":"6478_CR72","unstructured":"Centers for Disease Control and Prevention (2017) Bring Your Brave Campaign. https:\/\/www.cdc.gov\/cancer\/breast\/young_women\/bringyourbrave\/health_care_provider_education\/risk_assessment_tools.htm. Accessed 1 June 2021"},{"issue":"2","key":"6478_CR73","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10549-016-3686-2","volume":"155","author":"S Biswas","year":"2016","unstructured":"Biswas S, Atienza P, Chipman J et al (2016) A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat 155(2):375\u2013383","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"6478_CR74","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1245\/s10434-014-3921-1","volume":"21","author":"L Brannon Traxler","year":"2014","unstructured":"Brannon Traxler L, Martin ML, Kerber AS et al (2014) Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative. Ann Surg Oncol 21(10):3342\u20133347","journal-title":"Ann Surg Oncol"},{"key":"6478_CR75","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002916","author":"MS DeFrancesco","year":"2018","unstructured":"DeFrancesco MS, Waldman RN, Pearlstone MM et al (2018) Hereditary cancer risk assessment and genetic testing in the community-practice setting. Obstet Gynecol. https:\/\/doi.org\/10.1097\/AOG.0000000000002916","journal-title":"Obstet Gynecol"},{"issue":"3","key":"6478_CR76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/IGC.0b013e318280f2b4","volume":"23","author":"CB Powell","year":"2013","unstructured":"Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A (2013) Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer 23(3):431\u2013436","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"6478_CR77","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10463356.2018.1525993","volume":"33","author":"T Pal","year":"2018","unstructured":"Pal T, Radford C, Weidner A, Tezak AL, Cragun D, Wiesner GL (2018) The Inherited Cancer Registry (ICARE) initiative: an academic-community partnership for patients and providers. Oncol Issues 33(6):54\u201363","journal-title":"Oncol Issues"},{"issue":"7","key":"6478_CR78","doi-asserted-by":"crossref","first-page":"841","DOI":"10.6004\/jnccn.2020.7546","volume":"18","author":"D Cragun","year":"2020","unstructured":"Cragun D, Weidner A, Tezak A, Zuniga B, Wiesner GL, Pal T (2020) A web-based tool to automate portions of pretest genetic counseling for inherited cancer. J Natl Compr Cancer Netw 18(7):841\u2013847","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"6478_CR79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2016.07.094","volume":"143","author":"CH Watson","year":"2016","unstructured":"Watson CH, Ulm M, Blackburn P et al (2016) Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma. Gynecol Oncol 143(1):109\u2013112","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6478_CR80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.c.31602","volume":"178","author":"K Stoll","year":"2018","unstructured":"Stoll K, Kubendran S, Cohen SA (2018) The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine. Am J Med Genet C 178(1):24\u201337","journal-title":"Am J Med Genet C"},{"issue":"8","key":"6478_CR81","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41436-020-0797-2","volume":"22","author":"MLG Hallquist","year":"2020","unstructured":"Hallquist MLG, Tricou EP, Hallquist MN et al (2020) Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic. Genet Med 22(8):1348\u20131354","journal-title":"Genet Med"},{"key":"6478_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1343","author":"X Bracke","year":"2020","unstructured":"Bracke X, Roberts J, McVeigh TP (2020) A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1\/BRCA2 genetic testing. J Genet Couns. https:\/\/doi.org\/10.1002\/jgc4.1343","journal-title":"J Genet Couns"},{"key":"6478_CR83","unstructured":"MyGeneCounsel (2019) White paper: how often do medical management guidelines change for people with germline genetic findings? https:\/\/www.mygenecounsel.com\/wp-content\/uploads\/2019\/10\/How-Often-Do-Medical-Management-Guidelines-Change.pdf?utm_source=mailchimp&utm_campaign=0300b2cee1f0&utm_medium=page. Accessed 10 Dec 2019"},{"issue":"4","key":"6478_CR84","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.pec.2020.12.019","volume":"104","author":"M Dean","year":"2021","unstructured":"Dean M, Tezak AL, Johnson S et al (2021) Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers. Patient Educ Couns 104(4):720\u2013725","journal-title":"Patient Educ Couns"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06478-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:20:50Z","timestamp":1744154450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06478-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6478"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06478-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}